Consensus Statement
Recently published articles about Consensus Statement
Consensus Statement
Developing a Treatment-Resistant Depression Consultation Program, Part II: Assessment
May 7, 2025
Consensus recommendations about the goals of a consultation for treatment-resistant depression include establishing the primary diagnosis and comorbidities, clarifying symptoms, identifying goals, documenting treatment history, identifying treatment barriers, and...
Consensus Statement
Developing a Treatment-Resistant Depression Consultation Program, Part I: Practical and Logistical Considerations
April 28, 2025
Key practical considerations are described, including systems-level and financial issues; equity and access to TRD care for a diverse population; selecting a target population and facilitating referrals; communication between...
Consensus Statement
Synopsis of the VA/DOD Clinical Practice Guideline for Management of Bipolar Disorder
January 13, 2025
This synopsis focuses on clinically relevant recommendations related to identification and management of bipolar disorder, including the acute and maintenance phases of illness.
Consensus Statement
Screening, Diagnosis, and Treatment of Tardive Dyskinesia
January 28, 2020
Tardive dyskinesia remains a serious complication associated with dopamine receptor blocking agents. In this article, read guidance from experts on best practices for tardive dyskinesia screening, diagnosis, and treatment.
Recent JCP Articles on Consensus Statement
Original Research
Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial
August 25, 2025
In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.
Original Research
Levomilnacipran, but Not Duloxetine, Inhibits Serotonin and Norepinephrine Reuptake Throughout Its Therapeutic Range
August 25, 2025
Levomilnacipran and duloxetine are both potent serotonin reuptake inhibitors at all therapeutic regimens for MDD. Potent norepinephrine reuptake inhibition can be achieved from initiation with levomilnacipran, in contrast to...
Clinical and Practical Psychopharmacology
The Superiority of Clozapine Over SGAs in Patients With Treatment-Resistant Schizophrenia
August 25, 2025
Clozapine is associated with many adverse effects. Given the findings that olanzapine and risperidone may be as good as clozapine in treatment-resistant schizophrenia (TRS), it may be worth trialing...
